The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...

Current drug treatments have been incorporated into clinical practice guidelines, such as the NAEPP EPR-3 for asthma [101] and GOLD treatment guidelines for COPD, [102] both of which recognize the ...

Triple therapy may improve asthma symptoms, particularly among patients requiring systemic corticosteroids to treat severe exacerbations, a study finds. Adding long-acting muscarinic antagonists ...

In patients with chronic obstructive pulmonary disease (COPD), new initiation of beta2-agonist therapy, such as short-acting beta2-agonists (SABA), long-acting beta2-agonists (LABA), or inhaled ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

asthma inhaler In patients with COPD, tiotropium/olodaterol was associated with a lower risk for escalation to triple therapy or the development of adverse outcomes compared with LABA/ICS. After ...

When added to ICS, tiotropium and LABAs perform similarly for asthma patients. What is the effect of ICS/LABA controller therapy on asthma in patients with persistent cold airway hyperresponsiveness, ...

Please provide your email address to receive an email when new articles are posted on . Moving from a low-dose inhaled corticosteroid to a medium-dose inhaled corticosteroid plus a long-acting beta ...